Latest progress in the development of anti-2019-nCoV therapeutic drugs
10.3760/cma.j.issn.1674-2397.2022.02.003
- VernacularTitle:抗新型冠状病毒药物研制的最新动态
- Author:
Jifang SHENG
1
;
Yilin MA
Author Information
1. 传染病诊治国家重点实验室 国家感染性疾病临床医学研究中心 浙江大学医学院附属第一医院感染科，杭州 310003
- Keywords:
Coronavirus;
2019-nCoV;
Antiviral drugs;
Monoclonal neutralizing antibody
- From:
Chinese Journal of Clinical Infectious Diseases
2022;15(2):103-109
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, great progress has been made in small molecule therapeutic drugs and monoclonal neutralizing antibody preparations against 2019-nCoV. At least 5 oral drugs (Monupavir, AT-527, Proclutamide, Paxlovid and S-217622) and 2 monoclonal antibodies (Ambavirumab/Romisevirumab combination and Sotrovimab) have completed phase Ⅲ clinical trials exhibiting excellent antiviral effects. This article reviews the research progress of these 7 drugs to provide reference for clinical application.
